TriLink BioTechnologies, a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, introduces CleanCap – a patented mRNA capping method that overcomes many drawbacks of existing technology. CleanCap, which is available built into TriLink BioTechnologies products or in bulk for customer use, exhibits superior capping efficiencies for higher yield, along with time and cost savings.
"Capping is a critical process in creating viable mRNA constructs that remain biologically active and avoid self/non-self intracellular responses,” explains Anton McCaffrey, Ph.D., senior director of R&D for TriLink BioTechnologies. “By changing the chemical approach and streamlining the workflow, we can deliver an all-around better capping product, whether the customer buys it in bulk for his/her own capping, or purchases mRNA from us that incorporates the technology."
CleanCap mRNA is stocked and available from TriLink BioTechnologies for common applications and experiments in standard constructs such as CRISPR/Cas9 gene editing, reporter gene, gene replacement, dye-labeled and antigens. Custom mRNA constructs with CleanCap technology can also be ordered.
Founded in 1996, TriLink BioTechnologies is a global leader in the synthesis of high-quality nucleic acid and mRNA products for research, diagnostics, therapeutics and OEM customers. TriLink BioTechnologies products are instrumental in the discovery and development processes in gene and oligonucleotide therapy, nucleoside chemotherapy and diagnostics. The company is ISO 9001 certified and is compliant with ICH Q7, 21 CFR 210 and 21 CFR 820. TriLink BioTechnologies is headquartered in San Diego, Calif., where it also maintains its manufacturing facilities. The company was acquired by Maravai LifeSciences in 2016.
David Weber, Chief Commercial Officer